|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Effectiveness of exercise in hepatic fat mobilization in nonalcoholic fatty liver disease: Systematic review显示文摘AIM: To investigate the efficacy of exercise interventions on hepatic fat mobilization in non-alcoholic fatty liver disease(NAFLD) patients.METHODS: Ovid-Medline, Pub Med, EMBASE and Cochrane database were searched for randomized trials and prospective cohort studies in adults aged ≥ 18 which investigated the effects of at least 8 wk of exercise only or combination with diet on NAFLD from 2010 to 2016. The search terms used to identify articles, in which exercise was clearly described by type, duration, intensity and frequency were: 'NASH', 'NAFLD', 'nonalcoholic steatohepatitis', 'non-alcoholic fatty liver disease', 'fat', 'steatosis', 'diet', 'exercise', 'MR spectroscopy' and 'liver biopsy'. NAFLD diagnosis, as well as the outcome measures, was confirmed by either hydrogen-magnetic resonance spectroscopy(H-MRS) or biopsy. Trials that included dietary interventions along with exercise were accepted if they met all criteria. RESULTS: Eight studies met selection criteria(6 with exercise only, 2 with diet and exercise with a total of 433 adult participants). Training interventions ranged between 8 and 48 wk in duration with a prescribed exercise frequency of 3 to 7 d per week, at intensities between 45% and 75% of VO2 peak. The most commonly used imaging modality was H-MRS and one study utilized biopsy. The effect of intervention on fat mobilization was 30.2% in the exercise only group and 49.8% in diet and exercise group. There was no difference between aerobic and resistance exercise intervention, although only one study compared thetwo interventions. The beneficial effects of exercise on intrahepatic triglyceride(IHTG) were seen even in the absence of significant weight loss. Although combining an exercise program with dietary interventions augmented the reduction in IHTG, as well as improved measures of glucose control and/or insulin sensitivity, exercise only significantly decreased hepatic lipid contents.CONCLUSION: Prescribed exercise in subjects with NAFLD reduces IHTG independent of dietary intervention. Diet and exercise was more effective than exercise alone in reducing IHTG. | Pegah Golabi Cameron T Locklear Patrick Austin Sophie Afdhal Melinda Byrns Lynn Gerber Zobair M Younossi | 2016 | World Journal of Gastroenterology2016，22，27： | 30 |
| 2 | Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study显示文摘 | Patrick Marcellin Edward Gane Maria Buti Nezam Afdhal William Sievert Ira M Jacobson Mary Kay Washington George Germanidis John F Flaherty Raul Aguilar Schall Jeffrey D Bornstein Kathryn M Kitrinos G Mani Subramanian John G McHutchison E Jenny Heathcote | 2012 | The Lancet2012，，： | 14 |
| 3 | Interleukin-28B Polymorphism Improves Viral Kinetics and Is the Strongest Pretreatment Predictor of Sustained Virologic Response in Genotype 1 Hepatitis C Virus显示文摘 | Alexander J. Thompson Andrew J. Muir Mark S. Sulkowski Dongliang Ge Jacques Fellay Kevin V. Shianna Thomas Urban Nezam H. Afdhal Ira M. Jacobson Rafael Esteban Fred Poordad Eric J. Lawitz Jonathan McCone Mitchell L. Shiffman Greg W. Galler William M. Lee | 2010 | Gastroenterology2010，，1： | 7 |
| 4 | Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection显示文摘 | Nezam Afdhal Stefan Zeuzem Paul Kwo Mario Chojkier Norman Gitlin Massimo Puoti Manuel Romero-Gomez Jean-Pierre Zarski Kosh Agarwal Peter Buggisch Graham R. Foster Norbert Br?u Maria Buti Ira M. Jacobson G. Mani Subramanian Xiao Ding Hongmei Mo Jenny C. Ya | 2014 | The New England Journal of Medicine2014，，： | 6 |
| 5 | Tolvaptan, an oral vasopressin antagonist, in the treatment of hyponatremia in cirrhosis显示文摘 | Andrés Cárdenas Pere Ginès Paul Marotta Frank Czerwiec John Oyuang Mónica Guevara Nezam H Afdhal | 2011 | Journal of Hepatology2011，，3： | 6 |
| 6 | Liver cirrhosis显示文摘 | Detlef Schuppan Nezam H Afdhal | 2008 | The Lancet . 2008 (9615)2008，，： | 4 |
| 7 | Liver cirrhosis显示文摘 | Detlef Schuppan Nezam H Afdhal | 2008 | The Lancet2008，，9615： | 4 |
| 8 | O68 SOFOSBUVIR AND RIBAVIRIN FOR THE TREATMENT OF CHRONIC HCV WITH CIRRHOSIS AND PORTAL HYPERTENSION WITH AND WITHOUT DECOMPENSATION: EARLY VIROLOGIC RESPONSE AND SAFETY显示文摘 | N. Afdhal G. Everson J.L. Calleja G. McCaughan W.T. Symonds J. Denning L. McNair J.G. McHutchison S. Arterburn M. Charlton R. Reddy T. Asselah E. Gane X. Forns | 2014 | Journal of Hepatology2014，，1： | 3 |
| 9 | Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial显示文摘 | Kris V Kowdley Eric Lawitz Israel Crespo Tarek Hassanein Mitchell N Davis Michael DeMicco David E Bernstein Nezam Afdhal John M Vierling Stuart C Gordon Jane K Anderson Robert H Hyland Hadas Dvory-Sobol Di An Robert G Hindes Efsevia Albanis William T Symo | 2013 | The Lancet2013，，9883： | 3 |
| 10 | Silymarin Ascending Multiple Oral Dosing Phase I Study in Noncirrhotic Patients With Chronic Hepatitis C显示文摘 | Roy L. Hawke Sarah J. Schrieber Tedi A. Soule Zhiming Wen Philip C. Smith Rajender K. Reddy Abdus S. Wahed Steven H. Belle Nezam H. Afdhal Victor J. Navarro Josh Berman Qi-Ying Liu Edward Doo Michael W. Fried | 2010 | Journal of Clinical Pharmacology2010，，4： | 2 |
| 11 | Evaluation of serum biomarkers of fibrosis and injury in Egyptian patients with chronic hepatitis C显示文摘 | Gamal Esmat Mohamed Metwally Khalid R. Zalata Shahinaz Gadalla Mohamed Abdel-Hamid Amr Abouzied Abdel-Aziz Shaheen Maissa El-Raziky Hani Khatab Sherif El-Kafrawy Nabiel Mikhail Laurence S. Magder Nezam H. Afdhal G. Thomas Strickland | 2007 | Journal of Hepatology2007，，4： | 2 |
| 12 | Eltrombopag Increases Platelet Numbers in Thrombocytopenic Patients With HCV Infection and Cirrhosis, Allowing for Effective Antiviral Therapy显示文摘 | Nezam H. Afdhal Geoffrey M. Dusheiko Edoardo G. Giannini Pei–Jer Chen Kwang–Hyub Han Aftab Mohsin Maribel Rodriguez–Torres Sorin Rugina Igor Bakulin Eric Lawitz Mitchell L. Shiffman Ghias–Un–Nabi Tayyab Fred Poordad Yasser Mostafa Kamel Andres Brainsky Ja | 2014 | Gastroenterology2014，，2： | 2 |
| 13 | Circulating MicroRNAs as Biomarkers for Hepatocellular Carcinoma显示文摘 | Kevin Z. Qu Ke Zhang HaiRong Li Nezam H. Afdhal Maher Albitar | 2011 | Journal of Clinical Gastroenterology2011，，4： | 2 |
| 14 | The new paradigm of hepatitis C therapy: integration of oral therapies into best practices显示文摘 | N. H. Afdhal S. Zeuzem R. T. Schooley D. L. Thomas J. W. Ward A. H. Litwin H. Razavi L. Castera T. Poynard A. Muir S. H. Mehta L. Dee C. Graham D. R. Church A. H. Talal M. S. Sulkowski I. M. Jacobson | 2013 | J Viral Hepat2013，，11： | 2 |
| 15 | Hepatitis C virus (HCV) specific cytotoxic T lymphocytes recognize epitopes in the core and envelope proteins of HCV显示文摘 | Koziel M J Dudley D Afdhal N | 1993 | J Virol1993，67，12： | 2 |
| 16 | Peginterferon and Ribavirin Treatment in African American and Caucasian American Patients With Hepatitis C Genotype 1显示文摘 | Hari S. Conjeevaram Michael W. Fried Lennox J. Jeffers Norah A. Terrault Thelma E. Wiley–Lucas Nezam Afdhal Robert S. Brown Steven H. Belle Jay H. Hoofnagle David E. Kleiner Charles D. Howell | 2006 | Gastroenterology2006，，2： | 2 |
| 17 | echnology evaluation:A critical step in the clinical utilizati on of novel diagnostic tests for liver fibrosis显示文摘 | Afdhal NH Curry MT | 2002 | J H epatology2002，46，4： | 1 |
| 18 | Conservative management of perforated duodenal ulcer显示文摘 | Keane TE Dillon B Afdhal NH | 1988 | Br J Surg1988，75，6： | 1 |
| 19 | Identification of a 130-kilodalton human billaryconcanavalin a binding protein as aminopeptidase N显示文摘 | Offner GD Gong D Afdhal NH | 1994 | Gastroenterology1994，106，3： | 1 |
| 20 | Overexpression of estrogen receptor alpha increases hepatic cholesterogenesis, leading to biliary hypersecretion in mice 显示文摘 | Wang HH Afdhal NH Wang DQ | 2006 | J Lipid Res2006，47，4： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员